
|Articles|March 22, 2022
Daily Medication Pearl: Asmanex HFA
Author(s)Saro Arakelians, PharmD
Asmanex HFA is a corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older
Advertisement
Medication Pearl of the Day: Asmanex HFA 100 mcg (mometasone furoate)
Indication:Asmanex HFA is a corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older.
Insight:
- Dosing: In patients 12 years of age and older, 2 inhalations twice daily of Asmanex HFA 100 mcg or 200 mcg.
- Dosage forms: Inhalation aerosol containing 100 mcg or 200 mcg of mometasone furoate per actuation.
- Adverse events: Most common adverse reactions reported in greater than or equal to 3% of patients included nasopharyngitis, headache, sinusitis, bronchitis, and influenza.
- Mechanism of action: Mometasone furoate is a corticosteroid demonstrating potent anti-inflammatory activity.
- Manufacturer: Merck
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
COVID-19 mRNA Vaccines May Boost Immunotherapy Response in Cancer
2
KEYNOTE Trial Data Presented at ESMO 2025 Congress Reiterate Pembrolizumab’s Benefits in NSCLC
3
Court Ruling Highlights Risks of Improper Dose Adjustments
4
States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments
5















































































































































































































